WINTON GROUP Ltd acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 90,504 shares of the biopharmaceutical company’s stock, valued at approximately $10,633,000. WINTON GROUP Ltd owned approximately 0.10% of Alnylam Pharmaceuticals at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. State of Wisconsin Investment Board raised its holdings in shares of Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the period. Utah Retirement Systems raised its holdings in shares of Alnylam Pharmaceuticals by 1.5% during the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 200 shares during the period. Prudential Financial Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock valued at $3,818,000 after buying an additional 398 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.

Several brokerages recently commented on ALNY. BidaskClub upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. JMP Securities raised their target price on Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, September 20th. Barclays raised their target price on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an “overweight” rating in a report on Wednesday, November 8th. Piper Jaffray Companies reiterated an “overweight” rating and set a $110.00 target price (down from $126.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Finally, FBR & Co began coverage on Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a “buy” rating and a $150.00 target price on the stock. Three analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $121.85.

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at $129.74 on Wednesday. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals, Inc. has a twelve month low of $35.98 and a twelve month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. During the same quarter in the prior year, the firm earned ($1.21) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 24.8% compared to the same quarter last year. sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current year.

In other news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the transaction, the president now owns 165,399 shares in the company, valued at approximately $16,539,900. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Barry E. Greene sold 85,316 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 363,212 shares of company stock worth $44,032,736 over the last 90 days. 4.30% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “90,504 Shares in Alnylam Pharmaceuticals, Inc. (ALNY) Acquired by WINTON GROUP Ltd” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.watchlistnews.com/90504-shares-in-alnylam-pharmaceuticals-inc-alny-acquired-by-winton-group-ltd/1732065.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.